
|Videos|May 20, 2021
The Ever-Expanding Multiple Sclerosis Therapeutics
Join Ahmed Obeidat, MD, PhD; Mitchell Freedman, MD; and Suma Shah, MD, for the second program of this monthly series as they discuss the evolution of therapeutics for the treatment of multiple sclerosis.
Advertisement
————————————
Panelists
- Ahmed Obeidat, MD, PhD
Assistant Professor, Department of Neurology, Neuroimmunology and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin - Suma Shah, MD
Director, MS & Neuroimmunology Fellowship, Duke University School of Medicine - S. Mitchell Freedman, MD FAAN
Adjunct Professor of Neurology, University of North Carolina-Chapel Hill
Key Learning Objectives
- Virtual patient visits during COVID-19 when treating MS
- Changing barriers to treating MS
- Evolution of monitoring safety and efficacy of therapy
- The future of treating MS
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Noninvasive Spinal Cord Stimulation Plus Therapy Shows Promise for Improving Function in MS
2
Phase 3 CAPTIVATE Trial of Claseprubart in CIDP Now Enrolling, Trial Design Presented at PNS 2026
3
Phase 2a Study of Ignaseclant Suggests Strength and Functional Benefits in Charcot-Marie-Tooth Disease
4
Efgartigimod Shows Non-Inferior Disability Improvement and Greater Muscle Strength Recovery Versus Plasma Exchange in Real-World GBS Study
5














